By Zach Taft, CEO, IgniteData
As we close 2025, I feel both proud and energized. Proud of what our team and partners
achieved together, and energized by what these results unlock next.
IgniteData exists to remove friction from clinical trial data exchange so research teams can
focus on patients and accelerate drug development. In 2025, that mission moved decisively
from pilot to global scale.
Precision at Scale
This was a year of meaningful scale, not just growth. We achieved 786 percent year-over-year
site network growth, partnered with 8 of the top 10 U.S. cancer centers, and activated 17 of
the top 30. Today, 81 percent of NCI-designated clinical research sites are engaged in the
IgniteData network.
site network growth, partnered with 8 of the top 10 U.S. cancer centers, and activated 17 of
the top 30. Today, 81 percent of NCI-designated clinical research sites are engaged in the
IgniteData network.
We also expanded beyond academic centers, onboarding 40+ community oncology sites and
extending globally across Canada, Argentina, Australia, and Germany. High-quality clinical
data should move efficiently, regardless of location.
Performance That Matches the Moment
Growth matters only if it delivers results. In 2025, our product, Archer, did just that.
We saw a 676 percent increase in enrolled patients, a 10x+ increase in exported
datapoints, and a 489 percent increase in live studies. At the same time, the market reached
a clear inflection point. Sponsors and sites are no longer debating whether interoperability
works. They are focused on how fast it can scale.
We saw a 676 percent increase in enrolled patients, a 10x+ increase in exported
datapoints, and a 489 percent increase in live studies. At the same time, the market reached
a clear inflection point. Sponsors and sites are no longer debating whether interoperability
works. They are focused on how fast it can scale.
Archer met that moment by enabling reliable, standards-based data exchange that helps trials
move faster and therapies reach patients sooner.
Sponsor Momentum
Sponsor adoption accelerated significantly in 2025. We achieved 250 percent sponsor growth
in a single year. This accelerated adoption is in part due to an 87% reduction in queries and a
time to data reduction from an industry average of 30 days to less than 3 days. This reflects
in a single year. This accelerated adoption is in part due to an 87% reduction in queries and a
time to data reduction from an industry average of 30 days to less than 3 days. This reflects
increasing confidence in Archer as a production-ready platform and in IgniteData as a
long-term partner.
Gratitude and Looking Ahead
None of this progress happens without exceptional people. Thank you to the IgniteData team,
our site and sponsor partners, and the organizations that chose to build with us. Your trust and
collaboration shaped this year.
our site and sponsor partners, and the organizations that chose to build with us. Your trust and
collaboration shaped this year.
If 2025 was about execution at scale, 2026 will be about acceleration. We enter the next year
with a proven network, a mature platform, and a market ready to improve clinical trials at speed.
Together, we are building the foundation for faster research and faster access to new
treatments.
Thank you for being part of the journey.
Zach Taft